- COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES AND CANCER
-
The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II formula III, formula IV, formula V, formula VI, formula VII, and formula VIII and the methods for the treatment of inflammatory skin diseases and cancer may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of facial hirsutism, GI Polyps, rosacea, acne, melanoma, psoriasis, dermatitis and cancer including gliomas, gastrointestinal polyps, anaplastic astrocytoma and metastatic cancers.
- -
-
Paragraph 00118
(2020/01/11)
-
- R (+) - thioctic acid - L - lysine salt of the new crystal and its preparation method
-
The invention relates to the field of pharmaceutical chemistry, specifically to a new crystal form of R(+)-thioctic acid-L-lysinate, namely its crystal form I and its preparation method. The invention also relates to a pharmaceutical composition containing the new crystal form and an application of the pharmaceutical composition in the preparation of drugs for treating paresthesia caused by diabetic peripheral neuropathy. By the use of Cu-K alpha radiation, the X-ray power diffraction of R(+)-thioctic acid-L-lysinate crystal form I has diffraction peaks at 5.012, 7.589, 10.072, 12.549, 15.036, 16.688, 18.627, 19.356, 25.064 and 27.611 when expressed with 2 theta degrees, wherein the error range of 2 theta value is +/- 0.2.
- -
-
Paragraph 0038; 0039; 0040; 0041; 0042; 0043; 0044; 0045
(2017/08/26)
-